CureVac stock was delisted after its BioNTech merger
Published on 09/24/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CureVac stock was delisted after a merger that exchanged each CVAC share for 0.0520 new BNTX shares on January 9, 2026. The former vaccine developer now sits within BioNTech's broader manufacturing review, with decisions on potential divestment options scheduled through the end of September.
Merger changed the share structure
According to Robinhood, CureVac N.V. completed a stock merger on January 9, 2026. The exchange ratio was 0.0520 BNTX shares for each old CVAC share, and the same corporate-action record lists the security as delisted pending a stock liquidation.
The January transaction separates the operating story from the former public-market quote. CureVac stock can therefore be assessed through BioNTech's ownership and strategic decisions rather than through a regular CVAC trading price.
BioNTech reviews divestment options
BioNTech said on August 27, 2026, that it was exploring divestment options for its direct and indirect subsidiaries CureVac and JPT, alongside manufacturing sites in Germany and Singapore. The company said the review of CureVac's sites in Germany and abroad would continue through the end of September.
The wording describes an ongoing review rather than a completed sale. That distinction matters because the potential outcome concerns CureVac's operating assets and sites, while the former CVAC shares had already undergone the 0.0520-to-1 BNTX exchange in January.
Sites remain the key value question
SWR reported on September 23, 2026, that BioNTech's review affects CureVac's Tübingen operations and that around 820 jobs were at risk. The site decision now carries more practical significance than a conventional earnings catalyst because the former public listing no longer supplies a daily equity signal.
CVAC listing ended in January
CureVac stock's former Nasdaq listing ended after the January 9, 2026 merger, when each CVAC share converted into 0.0520 BNTX shares. The next concrete milestone is BioNTech's review of CureVac's sites through the end of September 2026.
CureVac at a glance
- Company: CureVac N.V.
- Ticker: CVAC
- Sector / Industry: Healthcare / Biotechnology
- Former trading venue: Nasdaq
- Former share conversion: 0.0520 BNTX shares per CVAC share on January 9, 2026
